Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorUtomo, Tomi Suryo
dc.descriptionRefleksi Hukum : Jurnal Ilmu Hukum, Edisi April 2009, p. 21-40id
dc.description.abstractThe existence of the Doha Declaration provides developing and least developed countries with potential strategies (safeguards) to reduce the impact of pharmaceutical protection on public health. This declaration offers several policies that are derived from the TRIPS Agreement. One of these is compulsory license. A key question for implementing compulsory licensing after the Doha Declaration is how to implement it in developing and least developed countries which have no or insufficient domestic capacity to produce pharmaceutical products. This becomes a serious problem because according to Article 31 (f) of the TRIPS Agreement, the adoption of compulsory licenses in the WTO members is for the domestic market only. As a consequence, countries with little or no domestic capacity to produce pharmaceuticals cannot import pharmaceuticals products produced under compulsory licenses from other countriesen_US
dc.publisherFakultas Hukum Universitas Kristen Satya Wacanaid
dc.subjectDoha declarationen_US
dc.subjectpharmaceuticals productsen_US
dc.subjectcompulsory licensesen_US
dc.titleImplementasi Lisensi Wajib Terhadap Produk Obat yang Dipatenkan Pasca Deklarasi Dohaid
Appears in Collections:Refleksi Hukum 2009 - April

Files in This Item:
File Description SizeFormat 
ART_Tomi Suryo Utomo_Implementasi Lisensi Wajib_Abstract.pdfAbstract313.13 kBAdobe PDFView/Open
ART_Tomi Suryo Utomo_Implementasi Lisensi Wajib_Full text.pdfFull text430.89 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.